29-Jan-2026
Vanguard Total Stock Market ETF (VTI) Daily Update—1/29/26
TipRanks (Thu, 29-Jan 8:16 AM ET)
Vanguard Total Stock Market ETF (VTI) Daily Update—1/28/26
TipRanks (Wed, 28-Jan 8:28 AM ET)
Globe Newswire (Thu, 8-Jan 8:00 AM ET)
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Globe Newswire (Mon, 29-Dec 8:00 AM ET)
Globe Newswire (Tue, 23-Dec 8:00 AM ET)
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 13-Nov 4:05 PM ET)
Globe Newswire (Wed, 12-Nov 8:00 AM ET)
Globe Newswire (Mon, 10-Nov 8:00 AM ET)
Market Chameleon (Thu, 2-Oct 7:20 AM ET)
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Reviva Pharmaceuticals Holdings trades on the NASDAQ stock market under the symbol RVPH.
As of January 29, 2026, RVPH stock price climbed to $0.30 with 1,976,493 million shares trading.
RVPH has a beta of 2.03, meaning it tends to be more sensitive to market movements. RVPH has a correlation of 0.04 to the broad based SPY ETF.
RVPH has a market cap of $34.90 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, RVPH traded as high as $9.25 and as low as $.25.
The top ETF exchange traded funds that RVPH belongs to (by Net Assets): VTI, VXF.
RVPH has underperformed the market in the last year with a price return of -83.3% while the SPY ETF gained +16.5%. RVPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.1% and -14.8%, respectively, while the SPY returned +1.3% and +0.3%, respectively.
RVPH support price is $.28 and resistance is $.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVPH shares will trade within this expected range on the day.